email : Webview : NETRF announces new RFP to further advance Immunotherapy Initiative

Systematic Evaluation of the Immune Environment of Neuroendocrine Tumors

NETRF RELEASES REQUEST FOR PROPOSALS FOR THE SYSTEMATIC EVALUATION OF THE IMMUNE ENVIRONMENT OF NETS
Grant Part of Larger Immunotherapy Initiative

The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to announce a funding opportunity to characterize the immune microenvironment of carcinoid and pancreatic neuroendocrine tumors. This is the second of two RFPs that NETRF has announced in the last two weeks. This is a repeat RFP, where we have already funded projects from Dr. Matthew Kulke at Dana-Farber Cancer Institute and Dr. Tim Meyer at University College London Cancer Institute. These projects are examples of the type of work we are looking to continue to fund in order to help hone in on how NETs might be susceptible to immunotherapies. We are eager to continue exploring the possibility that immune based therapies may be useful in treating neuroendocrine tumor patients and therefore are inviting applicants to apply to study the immune microenvironment of neuroendocrine tumor samples. We expect to award multiple grants of $100,000 each, paid over a one-year period. LEARN MORE AND APPLY

NETRF RELEASES RFP FOR $1.2 MILLION ACCELERATOR GRANTS

Last week, NETRF announced its request for proposals (RFP) for breakthrough “Accelerator Grants” to advance its vital mission to cure neuroendocrine cancers (NETs). With these grants, NETRF is launching the most ambitious privately funded global research effort ever undertaken to control and cure neuroendocrine cancers. A special thank you to all of the organizations internationally that are helping us share this opportunity with their members: International Neuroendocrine Cancer Alliance (INCA), European Neuroendocrine Tumor Society (ENETS), North American Neuroendocrine Tumor Society (NANETS), and the Education and Research Foundation (ERF), along with its partners the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American College of Nuclear Medicine (ACNM). Letters of Intent are due October 14, 2016 and applications are due November 18, 2016. READ MORE

Elyse Gellerman, MHS, NETRF's
Senior Administrative Officer

NETRF WELCOMES NEW SENIOR ADMINISTRATIVE OFFICER
Elyse Gellerman Joins NETRF

We are very pleased to announce the arrival of Elyse Gellerman, MHS who will join the NET Research Foundation as Senior Administrative Officer, on September 14, 2016. In her role, she will manage operations and will work with the team to develop and implement the Foundation’s strategic, business, marketing and financial plans.

“I am proud to be joining the NETRF team, which has made such a significant contribution to research and understanding of neuroendocrine cancer,” says Ms. Gellerman. “I am excited to support this vital work on behalf of thousands of patients and their families.”

"Elyse brings a wealth of health care and non-profit experience and a deep, mission-centered commitment to our work," said Ron Hollander, NETRF Executive Director. "She has a track record of results-oriented management that will be invaluable as we accelerate the scope and pace of our research for cures." READ MORE

NET PATIENT CONFERENCE INFORMATION AND REGISTRATION
November 10, 2016: NYC NET Patient Education Conference

Thursday, November 10, 2016
Einstein College of Medicine
Robbins Auditorium

Please join us for this exciting FREE conference to learn more about the latest developments in research and clinical care for patients with neuroendocrine cancers. We will be bringing together distinguished medical professionals from the New York City region and beyond, and will feature a special global segment on what will be the worldwide observance of NET Cancer Day!

Co-chaired by NETRF Executive Director, Ron Hollander and Montefiore's Dr. Edward Wolin. Confirmed speakers also include:

Dr. Steven Libutti, Director, Montefiore Einstein Center for Cancer Care
Dr. David Metz, Perelman School of Medicine, University of Pennsylvania
Dr. Diane Reidy, Memorial Sloan Kettering Cancer Center
Dr. Richard Warner, Mount Sinai Hospital

Presentations will touch on key issues for both patients and caregivers, including advances in therapies, surgery options, immunotherapy research, PRRT treatment, symptom management, and interactive panels.

We are pleased to announce that this eUpdate
is sponsored by Novartis Pharmaceutical Corporation.

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

20 Park Plaza, Suite 478
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.

Subscribe to our email list.